Background Policymakers and researchers frequently compare the prices of medicines between countries. Such comparisons often serve as barometers of how pricing and reimbursement policies are performing. The aim of this study was to examine methodological challenges to comparing generic drug prices. Methods We calculated all commonly used price indices based on 2013 IMS Health data on sales of 3156 generic drugs in seven European countries. Results There were large differences in generic drug prices between countries. However, the results varied depending on the choice of index, base country, unit of volume, method of currency conversion, and therapeutic category. The results also differed depending on whether one looked at the prices charge...
Continued growth of spending on drugs in Health care, especially in the public sector encouraged ini...
Continued growth of spending on drugs in Health care, especially in the public sector encouraged ini...
Cross-country variability in regulatory frameworks, industrial policy, physician/pharmacy autonomy, ...
Abstract Background Policymakers and researchers frequently compare the prices of medicines between ...
Policy Points: Our study indicates that there are opportunities for cost savings in generic drug mar...
Our study indicates that there are opportunities for cost savings in generic drug markets in Europe ...
OBJECTIVE: To survey the price differences between originators and generics for a selected basket of...
The purpose of this paper is to examine the extent of generic competition in European countries, gi...
Background and importance: Rising drug prices are putting pressure on health care budgets. Policymak...
Background and importance: Rising drug prices are putting pressure on health care budgets. Policymak...
Background and importance: Rising drug prices are putting pressure on health care budgets. Policymak...
In this report we compare prices of pharmaceuticals between Norway and the following nine Western Eu...
In this report we compare prices of pharmaceuticals between Norway and the following nine Western Eu...
In this report we compare prices of pharmaceuticals between Norway and the following nine Western Eu...
Background and importance: Rising drug prices are putting pressure on health care budgets. Policymak...
Continued growth of spending on drugs in Health care, especially in the public sector encouraged ini...
Continued growth of spending on drugs in Health care, especially in the public sector encouraged ini...
Cross-country variability in regulatory frameworks, industrial policy, physician/pharmacy autonomy, ...
Abstract Background Policymakers and researchers frequently compare the prices of medicines between ...
Policy Points: Our study indicates that there are opportunities for cost savings in generic drug mar...
Our study indicates that there are opportunities for cost savings in generic drug markets in Europe ...
OBJECTIVE: To survey the price differences between originators and generics for a selected basket of...
The purpose of this paper is to examine the extent of generic competition in European countries, gi...
Background and importance: Rising drug prices are putting pressure on health care budgets. Policymak...
Background and importance: Rising drug prices are putting pressure on health care budgets. Policymak...
Background and importance: Rising drug prices are putting pressure on health care budgets. Policymak...
In this report we compare prices of pharmaceuticals between Norway and the following nine Western Eu...
In this report we compare prices of pharmaceuticals between Norway and the following nine Western Eu...
In this report we compare prices of pharmaceuticals between Norway and the following nine Western Eu...
Background and importance: Rising drug prices are putting pressure on health care budgets. Policymak...
Continued growth of spending on drugs in Health care, especially in the public sector encouraged ini...
Continued growth of spending on drugs in Health care, especially in the public sector encouraged ini...
Cross-country variability in regulatory frameworks, industrial policy, physician/pharmacy autonomy, ...